Skip to main content

HomeKisspeptin-10Legal status

Educational — Not Legal AdviceReviewed

Is Kisspeptin-10 legal? FDA status and US regulatory standing

Current status

Barred from compounding. Kisspeptin-10 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound (status recorded ).

Primary source: www.fda.gov

Federal legal status

FDA approval status

Kisspeptin-10 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound. No FDA approval. Phase 1/2 studies for hypogonadotropic hypogonadism and IVF trigger (NIH/academic). No NDA filed. Sold as research peptide outside of clinical trials.

Also known as

KP-10 · Metastin 45-54

Status history

  • Kisspeptin-10 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound. [source]

Frequently asked questions

Is Kisspeptin-10 FDA approved?
Kisspeptin-10 is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound (status recorded 2023-09-29). Primary source linked on this page.
Is Kisspeptin-10 legal to buy?
Kisspeptin-10 is available in the U.S. as a research-use-only compound. It is not FDA-approved and has been placed in a category of bulk substances that licensed pharmacies may not compound. Sale for human consumption is not permitted.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Content review: Regulatory status is sourced from the linked primary records and reviewed by the PeptideBase editorial team. This page is educational — not legal or medical advice. Last reviewed: .

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.

Free Guide

The Peptide Research Digest

Get our free provider vetting guide — plus weekly research briefings on peptide sourcing, COA verification, and clinical developments.

No spam.